The microculture-kinetic (MiCK) assay: The role of a drug-induced apoptosis assay in drug development and clinical care

Cancer Research

Volumn 72, Issue 16, 2012, Pages 3901-3905

  Bosserman, Linda ^a   Prendergast, Franklyn ^b   Herbst, Roy ^c   Fleisher, Martin ^d   Salom, Emery ^e   Strickland, Steven ^f   Raptis, Anastasios ^j   Hallquist, Allan ^g   Perree, Mathieu ^g   Rajurkar, Swapnil ^a   Karimi, Misagh ^a   Rogers, Karl ^h   Davidson, Dirk ⁱ   Willis, Carl ^h   Penalver, Manuel ^e   Homesley, Howard ^l   Burrell, Matthew ^m   Garrett, Audrey ⁿ   Rutledge, James ^o   Chernick, Michael ^k   Presant, Cary A ^a,g   more..

^a Wilshire Oncology Medical Group US Oncology   (United States)

^b MAYO CLINIC   (United States)

^c YALE CANCER CENTER   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e South Florida Gynecologic Oncology   (United States)

^f VANDERBILT INGRAM CANCER CENTER   (United States)

^g DiaTech Oncology   (United States)

^h Nashville Oncology Associates   (United States)

ⁱ Tennessee Plateau Oncology   (United States)

^j UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^k Lankenau Institute of Medicine   (United States)

^l WAKE FOREST SCHOOL OF MEDICINE   (United States)

^m NORTHSIDE HOSPITAL   (United States)

ⁿ Sacred Heart Medical Center Eugene   (United States)

^o University of Dayton   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CAPECITABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IDARUBICIN; IRINOTECAN; METHOTREXATE; OXALIPLATIN; PACLITAXEL; PEMETREXED;

ACUTE GRANULOCYTIC LEUKEMIA; ANALYTIC METHOD; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CELL CULTURE; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RELAPSE; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; CONCENTRATION RESPONSE; CORRELATIONAL STUDY; COST CONTROL; DRUG APPROVAL; DRUG CHOICE; DRUG RESEARCH; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG USE; HEALTH CARE COST; HUMAN; INCUBATION TIME; MEDICAL DECISION MAKING; MICROCULTURE KINETIC ASSAY; OPTICAL DENSITY; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CHRONIC DISEASE; DRUG DISCOVERY; DRUG SCREENING ASSAYS, ANTITUMOR; HL-60 CELLS; HUMANS; LEUKEMIA; NEOPLASMS;

EID: 84865146617     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-0681     Document Type: Review

References (14)

1. Kravtsov VD, Fabian I. Automated monitoring of apoptosis in suspension cell cultures. Lab Invest 1996;74:557-70. (Pubitemid 26072096)
2. Kravtsov VD. A novel microculture kinetic assay (MiCK assay) for malignant cell growth and chemosensitivity. Eur J Cancer 1994;30A: 1564-70. (Pubitemid 24343023)
3. Kravtsov VD, Daniel TO, Koury MJ. Comparative analysis of different methodological approaches to the in vitro study of drug-induced apoptosis. Am J Pathol 1999;155:1327-39. (Pubitemid 29488940)
4. Kravtsov VD, Greer J, Shyr Y, Haselton J, Whitlock JA, Goodman S, et al. Prediction of survival in acute nonlymphocytic leukemia. Blood 2001;98:214b.
5. Kravtsov VD, Greer JP, Whitlock JA, Koury MJ. Use of the microculture kinetic assay of apoptosis to determine chemosensitivities of leukemias. Blood 1998;92:968-80. (Pubitemid 28355481)
6. Ballard KS, Homesley HD, Hodson C, Presant CA, Rutledge J, Hallquist A, et al. Endometrial carcinoma in vitro chemosensitivity testing of single and combination chemotherapy regimens using the novel microculture kinetic apoptosis assay: implications for endometrial cancer treatment. J Gynecol Oncol 2010;21:45-9.
7. Salom EM, Penalver M, Homesley HD, Presant CA, Rutledge J, Burrell MO, et al. Can we increase response rate (RR) and overall survival (OS) by individualizing chemotherapy in ovarian cancer (OC): the role of new chemotherapy (CT) induced apoptosis assay. J Clin Oncol 28:15s, 2010 (suppl; abstr 5112).
8. Bosserman LD, Rajurkar SP, Rogers K, Davidson DC, Chernick M, Hallquist A, et al. Correlation of drug-induced apoptosis assay results with oncologist treatment decisions and patient response and survival. Cancer 2012 Feb 21. [Epub ahead of print].
9. Schultz R, Rothenberg M, Koury M, Hankins W, Kravtsov V. Sequence dependence using combinations of Alimta (pemetrexed sodium LY231514, MTA), gemcitabine and oxaliplatin in human colorectal carcinoma cell lines [abstract]. In: Proceedings of the 11th NCI-EORTC-AACR Symposium on New Drugs in Cancer; 2000 Nov 7- 10; Amsterdam, Netherlands.
10. Latimer G, Presant CA, Hallquist A, Perree M, Agapitos D. The value of personalized treatment planning: cost savings by the microculture kinetic chemosensitivity assay, evidence from a large American self-insured company. J Clin Oncol 2009;27 (suppl; abstr e17).
11. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366: 883-92.
12. Ugurel S, Schadendorf D, Pföhler C, Neuber K, Thoelke A, Ulrich J, et al. Dermatologic Cooperative Oncology Group. In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group. Clin Cancer Res 2006;12:5454-63. (Pubitemid 44497261)
13. Samson DJ, Seidenfeld J, Ziegler K, Aronson N. Chemotherapy sensitivity and resistance assays: a systematic review. J Clin Oncol 2004;22:3618-30. (Pubitemid 41103669)
14. Burstein HJ, Mangu PB, Somerfield MR, Schrag D, Samson D, Holt L, et al. American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. J Clin Oncol 2011;29:3328-30.